European Union´s Horizon 2020 – Lipum2020-06-23T06:45:31+00:00

OFFICAL PROJECT SITE 

Novel Target for Treatment of Chronic Inflammatory Diseases — Notid

1702, 2020

Lipum kallar till extra bolagsstämma

February 17th, 2020|

Aktieägarna i Lipum AB, org. nr. 556813-5999, kallas härmed till extra bolagsstämma tisdagen den 3 mars 2020, kl. 13:00 på Tvistevägen 48C i Umeå. Styrelsen föreslår att Dr Kristian Sandberg väljs som ordinarie styrelseledamot i Lipum AB. Ladda ned kallelse här »

1812, 2019

A milestone has been reached

December 18th, 2019|

After an intensive and targeted work, the cell line development of our lead drug candidate SOL-116 has been finalized. Now the production optimization and scale up has been initiated and that will provide access of non-GMP and GMP material during 2020. That will enable toxicity studies and start of clinical [...]

2911, 2019

Professor Anders Fasth joins the scientific advisory board

November 29th, 2019|

Press release November 29, 2019 Lipum has developed a biological drug candidate for treatment of chronic inflammatory diseases and aim for a better treatment of juvenile idiopathic arthritis (JIA), that affects children. Therefore, the scientific advisory board of the company is now strengthened with Anders Fasth, senior professor of pediatric [...]

2611, 2019

Pharma Outsourcing 2019

November 26th, 2019|

“How we selected our CMO partner for cell line and production development of Lipum´s lead candidate drug SOL-116” […]

1510, 2019

BioStock Life Science Summit

October 15th, 2019|

Life Science industry leaders, financing experts and qualified investors gather in Lund. Welcome to meet us at Biostock Life Science Summit, october 23th-24th. […]

3009, 2019

Lipum participates in investment and partnering meeting

September 30th, 2019|

Today, our COO, Pernilla Abrahamsson, is traveling to Paris to participate at French-Swedish Life Science Days 2019. The goal of the conference is to establish new contacts and identify business and collaboration opportunities. The conference will gather early stage and highly innovative medtech and biotech companies from Sweden and France, [...]

Program:
European Commission Horizon 2020
SME Instrument phase 1 No 744248
SME Instrument phase 2 No 829741

Project title:
Novel Target for Treatment of Chronic Inflammatory Diseases

Project budget:
3.2 M€

Funding from the EU:
2.2 M€

Start:
2018-11-01

End:
2020-07-31